Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/49747
Título: Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population
Autores/as: Saloranta, Carola
Guitard, Christiane
Pecher, Eckhard
De Pablos-Velasco, Pedro 
Lahti, Kaj
Brunel, Patrick
Groop, Leif
Clasificación UNESCO: 32 Ciencias médicas
3205 Medicina interna
320502 Endocrinología
Palabras clave: Type-2 Diabetes-Mellitus
Postchallenge Hyperglycemia
Cardiovascular-Disease
Fasting Glucose
Life-Style, et al.
Fecha de publicación: 2002
Publicación seriada: Diabetes Care 
Resumen: OBJECTIVE - The purpose of this study was to evaluate the metabolic effectiveness, safety and tolerability of nateglinide in subjects with impaired glucose tolerance (IGT) and to identify a dose appropriate for use in a diabetes prevention study.RESEARCH DESIGN AND METHODS - This multicenter, double-blind, randomized, parallel-group, fixed-dose study of 8 weeks' duration was performed in a total of 288 subjects with IGT using a 2:2:2:1 randomization. Subjects received nateglinide (30, 60, and 120 mg) or placebo before each main meal. Metabolic effectiveness was assessed during a standardized meal challenge performed before and after the 8-week treatment. All adverse events (AEs) were recorded, and confirmed hypoglycemia was defined as symptoms accompanied by a self-monitoring of blood glucose measurement less than or equal to3.3 mmol/l (plasma glucose less than or equal to 3.7 mmol/l).RESULTS - Nateglinide elicited a dose-related increase of insulin and a decrease of glucose during standardized meal challenges, with the predominant effect on early insulin release, leading to a substantial reduction in peak plasma glucose levels. Nateglinide was well tolerated, and symptoms of hypoglycemia were the only treatment-emergent AEs. Confirmed hypoglycemia occurred in 28 subjects receiving nateglinide (30 mg, 0 [0%] 60 mg, 5 [6.6%] 120 mg, 23 [26.7%]) and in 1 (2.3%) subject receiving placebo.CONCLUSIONS - Nateglinide was safe and effective in reducing postprandial hyperglycemia in subjects with IGT. Preprandial doses of 30 or 60 mg nateglinide would be appropriate to use for longer-term studies to determine whether a rapid-onset, rapidly reversible, insulinotropic agent can delay or prevent the development of type 2 diabetes.
URI: http://hdl.handle.net/10553/49747
ISSN: 0149-5992
DOI: 10.2337/diacare.25.12.2141
Fuente: Diabetes Care[ISSN 0149-5992],v. 25, p. 2141-2146
Colección:Artículos
Vista completa

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.